| Ortho Evra Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Ortho Evra 20 mcg-150 mcg/24 hr | film, extended release | transdermal | 24.0 hour(s) | OTC |
| Ortho Evra 20 mcg-150 mcg/24 hr | film, extended release | transdermal | 24.0 hour(s) | OTC |
Posted by momofns about 1 month ago
Did anybody gained a lot of weight with the patch? I have used it for about 12 mo and gained a lot of weight... I felt like a...
Posted by ziggyzaazaa 6 months ago
My heart hurt after being on it in 5 years, got it removed, and no longer had heart pain. I would have miniature heart attack...
Posted by iampixi13 9 months ago
Im on it right now, have been for about 2 years.. I haven't had any bad side effects, My boobs do get a bit bigger around the...
Weitz & Luxenberg Cautions the Public on the Use of Disreputable ... - Centre Daily Times
The firm's other active pharmaceutical litigations include actions against the manufacturers of Bextra, ReNu, Celebrex, and Ortho Evra.
Thu Mar 06 09:56:52 -0500 2008
Weitz & Luxenberg Stands with Petitioners against ''Ban Asbestos ... - Insurance News Net (press release)
The firm’ s other active pharmaceutical litigations include actions against the manufacturers of Bextra, ReNu, Celebrex, and Ortho Evra.
Tue Mar 04 10:13:47 -0500 2008
Weitz & Luxenberg Cautions the Public on the Use of Disreputable ... - Centre Daily Times
The firm's other active pharmaceutical litigations include actions against the manufacturers of Bextra, ReNu, Celebrex, and Ortho Evra.
Thu Mar 06 09:56:52 -0500 2008
ethinyl estradiol - A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)
norelgestromin